CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,057 enrolled
Drug / intervention
PF-06651600 +2 moredrug
Likely dose
PF-06651600 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04006457
NCT04006457Phase 3Completed
CompareCT.gov

A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

Pfizer·interventional·Posted Jul 5, 2019·Updated Apr 9, 2026

In Brief

A Phase 3 clinical trial evaluating PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, and 1 other intervention for Alopecia Areata. Completed, enrolled 1,057 participants across 144 sites in 17 countries.

Detailed Summary

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug. A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesArgentina, Australia, Canada, Chile, China, Colombia, Czechia, Germany, Japan, Mexico, Poland, Russia, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJul 5, 2019
Enrollment StartJul 18, 2019
Primary CompletionJun 25, 2024
Study CompletionFeb 26, 2026
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.0 years ago

Interventions

PF-06651600drug

50 mg oral tablets/capsules

Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccinebiological

Single intramuscular injection administered to patients participating in the vaccine sub-study

Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccinebiological

Single intramuscular injection administered to patients participating in the vaccine sub-study